Current use of intralesional cidofovir for recurrent respiratory papillomatosis

Derkay, Craig S.; Volsky, Peter G.; Rosen, Clark A.; Pransky, Seth M.; McMurray, J. Scott; Chadha, Neil K.; Froehlich, Patrick

doi:10.1002/lary.23673

Cited by 75 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CDV has also been employed to manage recalcitrant cases of verruca vulgaris, mosaic verruca plana, and different skin lesions caused by HPV (Stragier et al, 2002;Bonatti et al, 2007;Kralund et al, 2011;Field et al, 2009). Importantly, following the first report on the use of CDV for the treatment of severe RRP in 1998 (Snoeck et al, 1998), the application of the drug as adjuvant therapy for severe cases of RRR has been documented by several investigators (Derkay et al, 2013;Mikolajczak et al, 2012;Ksiazek et al, 2011;Derkay and Wiatrak, 2008). Although there were some anecdotal reports documenting serious adverse reactions in RRP in off-label use of CDV (Tjon Pian Gi et al, 2012), a multicentre retrospective chart review involving 16 hospitals from 11 countries worldwide with 635 RRP patients (of whom 275 were treated with CDV) was performed.…”

Section: In Vitro In Vivo and Clinical Evidences For The Anti-papillmentioning

confidence: 94%

“…In another recent study, it was concluded that CDV remains the leading option for adjuvant treatment of patients with RRP of all ages whose disease is difficult to manage with surgery alone. CDV represents an option to reduce the risks of frequent surgical debulking and airway obstruction in children and adults with recurrent or severe disease (Derkay et al, 2013). CDV is nowadays recognized as an adjuvant therapy for the management of this disease (Tjon Pian Gi et al, 2013;Graupp et al, 2013).…”

Section: In Vitro In Vivo and Clinical Evidences For The Anti-papillmentioning

confidence: 99%

See 1 more Smart Citation

Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia

et al. 2015

View full text Add to dashboard Cite

Acyclic nucleoside phosphonates (ANPs) are well-known for their antiviral properties, three of them being approved for the treatment of human immunodeficiency virus infection (tenofovir), chronic hepatitis B (tenofovir and adefovir) or human cytomegalovirus retinitis (cidofovir). In addition, cidofovir is mostly used off-label for the treatment of infections caused by several DNA viruses other than cytomegalovirus, including papilloma- and polyomaviruses, which do not encode their own DNA polymerases. There is considerable interest in understanding why cidofovir is effective against these small DNA tumor viruses. Considering that papilloma- and polyomaviruses cause diseases associated either with productive infection (characterized by high production of infectious virus) or transformation (where only a limited number of viral proteins are expressed without synthesis of viral particles), it can be envisaged that cidofovir may act as antiviral and/or antiproliferative agent. The aim of this review is to discuss the advances in recent years in understanding the mode of action of ANPs as antiproliferative agents, given the fact that current data suggest that their use can be extended to the treatment of non-viral related malignancies.

show abstract

Section: In Vitro In Vivo and Clinical Evidences For The Anti-papillmentioning

confidence: 94%

Section: In Vitro In Vivo and Clinical Evidences For The Anti-papillmentioning

confidence: 99%

Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The role of cidofovir in the therapy of recurrent laryngeal papillomatosis has not yet been sufficiently evaluated. Several studies have shown that when locally applied, cidofovir is virustatic without any side effects and, in particular, is able to significantly reduce the rate of recurrence [12,13]. The importance of evaluating the impact of any disease on the patient's quality of life and the outcome of various therapeutic interventions is increasing.…”

Section: Discussionmentioning

confidence: 99%

Voice improvement in patients with recurrent respiratory papillomatosis after combined treatment with cidofovir and CO2 laser surgery

et al. 2019

View full text Add to dashboard Cite

Mechanical debulking of laryngeal papillomas is associated with voice disorders due to impairment of the vocal fold's mucosa. Intraepithelial injection of cidofovir reduces damage to the laryngeal structures and thus improves vocal parameters. The aim of our study was to compare vocal quality before and after cidofovir and CO 2 laser treatment by means of objective phoniatric parameters and to obtain evidence concerning voice outcomes. The vocal parameters of 42 patients with RRP were assessed before and after intralesional cidofovir and CO 2 laser debulking treatment (Lumenis AcuPulse 40 CO 2 laser, wavelength 10.6 μm; Lumenis Ltd., Yokneam, Israel). The laser was used in SuperPulse ™ mode with power tailored on the target structures (average 7 W). The depth of tissue penetration was 1 mm with a single burst of energy lasting 0.3 ms. Most of the patients had previously undergone traditional surgery (1-105 procedures); in 7/42, the video stroboscopic examination revealed extensive scar tissue covering the mucosa of the vocal folds, limiting the mucosal wave. The significance level for all calculations was p < 0.05. Statistical analysis was performed using Statistica 10 by StatSoft Polska. The methodology included subjective voice evaluation (GRBAS), videostroboscopy, analysis of the acoustic laryngeal tone (MDVP), spectrographic analysis, and voice handicap index (VHI). The GRBAS scale during spontaneous conversation revealed better phonation results after cidofovir treatment in all 42 patients. Scars were not observed in the presented group. In the MDVP laryngeal tone analysis before surgery parameters defining the amplitude and frequency of laryngeal tone were significantly elevated compared to the state after surgery. After treatment, both jitter and shimmer were reduced in all subjects. Even more pronounced changes were observed in the spectrographic analysis. In all analyzed patients, there was a significant reduction in VHI scores showing improvement in voice self-assessment. A satisfactory improvement in voice quality was observed in all RRP patients treated with cidofovir and CO 2 laser.

show abstract

“…La Recurrent Respiratory Papillomatosis Task Force recomienda la utilización de cidofovir intralesional en pacientes que requieren procedimientos quirúrgicos laríngeos cada 2 o 3 meses. 9 Se han probado interferon alpha, antivirales (acyclovir, cidofovir, ribavirin), vacuna contra el HPV, terapia génica. No se ha observado curación con estos tratamientos.…”

Section: Discussionunclassified

Papilomatosis respiratoria recurrente. Caso clínico

Luong¹,

Scrigni²,

Ruvinsky³

et al. 2015

Arch Argent Pediat

View full text Add to dashboard Cite

Arch Argent Pediatr 2015;113(4):e203-e206 / e203Presentación de casos clínicos RESUMEN La papilomatosis respiratoria recurrente es una enfermedad rara que se caracteriza por el desarrollo de papilomas en toda la vía aérea. Es causada por el virus del papiloma humano. Su incidencia es de 4 por 100 000 en niños. La forma de transmisión es vertical durante el embarazo o el parto. Hay 130 variedades de virus del papiloma humano, de los cuales los tipos 6 y 11 son los que producen papilomatosis respiratoria recurrente, y especialmente el tipo 11 es el que desarrolla enfermedad más agresiva con recurrencia y progresión en todo el tracto respiratorio y, con menos frecuencia, en la región nasofaríngea. Se presenta un paciente de 7 años de edad con diagnóstico de papilomatosis respiratoria recurrente basado en la radiología y la endoscopía respiratoria, que permitió aislar el virus del papiloma humano tipo 11 en papilomas en laringe y tráquea y en material de lavado broncoalveolar. Palabras clave: papilomatosis respiratoria recurrente, virus del papiloma humano. ABSTRACTRecurrent respiratory papillomatosis (RRP) is a rare condition characterized by recurrent growth of papilloma in the respiratory tract. RRP is caused by human papilloma virus. Its incidence is 4 per 100 000 children. Vertical transmission of the virus during gestation or during delivery is the major route of contracting the disease in children. One hundred and thirty different human papilloma virus types have been identified. Types 6 and 11 are involved in RRP and type 11 develops more aggressive disease with recurrence and progression to the respiratory tract and also nasopharyngeal surface. We present a 7 year old boy with diagnosis of RRP based on radiology and endoscopy. Key words: recurrent respiratory papillomatosis, human papillomavirus.http://dx.doi.org/10.5546/aap.2015.e203 Papilomatosis respiratoria recurrente. Caso clínico Recurrent respiratory papillomatosis. Case report INTRODUCCIÓNLos papilomas son tumores benignos que afectan el aparato respiratorio (inclusive la región nasofaríngea). 1 La papilomatosis respiratoria recurrente (PRR) es una enfermedad rara que afecta pacientes en edad pediátrica y adultos. Se caracteriza por el desarrollo de papilomas que comprometen la laringe, las cuerdas vocales y se extiende a todo el árbol bronquial y parénquima pulmonar, y la región nasofaríngea. Es causada por el virus denominado papiloma virus humano (human papiloma virus; HPV, por sus siglas en inglés). La forma de transmisión es vertical durante el embarazo o parto. Hay 130 variedades de HPV, de las cuales los tipos 6 y 11 son los que producen PRR, y especialmente el tipo 11 es el que desarrolla enfermedad más agresiva con recurrencia y progresión en todo el tracto respiratorio.En el presente artículo, se describe un paciente de 7 años con esta patología. CASO CLÍNICOP a c i e n t e d e 7 a ñ o s c o n d i a g n ó s t i c o de papilomatosis laríngea desde los 4 años. Requirió múltiples microcirugías laríngeas para la resección de los papilomas. El ...

show abstract

Current use of intralesional cidofovir for recurrent respiratory papillomatosis

Cited by 75 publications

References 15 publications

Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia

Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia

Voice improvement in patients with recurrent respiratory papillomatosis after combined treatment with cidofovir and CO2 laser surgery

Papilomatosis respiratoria recurrente. Caso clínico

Contact Info

Product

Resources

About